What is STTK's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.60B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for STTK?

P/E (TTM) is n/a and 52-week range is $1.70 to $8.33 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s STTK figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for STTK?

The company profile lists revenue (TTM) near $696K, net income (TTM) near $-700M, EPS (TTM) near $-0.51 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Shattuck Labs Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in Austin, Texas, US, 90.4M shares outstanding, ISIN US82024L1035 when available from company profile and filing metadata.

Shattuck Labs Inc

$STTK

Health Care · Biotechnology

IR Run Scenarios

$5.97

+5.48%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

Shattuck Labs, Inc. is a biotechnology company, which engages in the research and development of potential treatments for inflammatory and immune-mediated diseases. The company is headquartered in Austin, Texas and currently employs 40 full-time employees. The company went IPO on 2020-10-09. The firm is engaged in the development of treatments for inflammatory and immune-mediated diseases. Its lead product candidate, SL-325, is a monoclonal antibody that is designed to bind to death receptor 3 (DR3) and inhibit its interaction with its ligand, TL1A. TL1A is a costimulatory ligand in the tumor necrosis factor superfamily, which activates immune responses through binding a single receptor, DR3. The firm is conducting a Phase I clinical trial in healthy volunteers. In addition, the Company is also developing SL-425, a half-life extended version of SL-325. The company is also developing multiple preclinical DR3-based bispecific antibodies, which are designed to inhibit both the DR3/TL1A axis and another biologically relevant target for the treatment of patients with inflammatory bowel disease.

Employees

Website

www.shattucklabs.com/

IPO

2020-10-09

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)

Net income (TTM)